皮肤免疫相关不良事件与抗程序性细胞死亡1及抗程序性细胞死亡配体1治疗患者生存改善的关联
这项回顾性队列研究利用TriNetX Diamond Network数据库,纳入7008例抗PD-1或抗PD-L1治疗后6个月内发生皮肤免疫相关不良事件(cirAE)的恶性肿瘤患者及7008例匹配对照,分析cirAE与总生存的关联。结果显示,瘙痒、药疹、干燥症、非特异性皮疹及任何cirAE的发生均与死亡风险降低显著相关。
要点
- 瘙痒(HR 0.695)、药疹(HR 0.755)、干燥症(HR 0.626)、非特异性皮疹(HR 0.704)及任何cirAE(HR 0.778)均与死亡风险降低显著相关。
- 银屑病(HR 0.703)与扁平苔藓/苔藓样皮炎(HR 0.511)亦与生存改善显著相关。
- 湿疹性皮炎、白癜风、大疱性类天疱疮及Grover病均与强保护性临床效应相关,但置信区间较宽。
核心结论
- 这项队列研究的结果提示,cirAE的发生与ICI治疗应答及患者生存强相关。
研究设计与样本
- 回顾性队列研究,使用TriNetX Diamond Network数据库(来自美国及欧洲超过2亿患者的健康记录与理赔数据)进行人群水平队列分析。
- 纳入7008例因消化器官、支气管或肺、皮肤黑色素瘤及泌尿道恶性肿瘤接受抗PD-1或抗PD-L1治疗后发生cirAE的合格患者,并与7008例匹配对照比较。
- 暴露定义为抗PD-1或抗PD-L1治疗后6个月内发生cirAE;采用Cox比例风险模型进行6个月分析,调整人口学特征、癌症类型及癌症分期。
主要发现
- 7008例患者(女性3036例[43.3%];平均[SD]年龄68.2[11.2]岁)与7008例对照(女性3044例[43.4%];平均[SD]年龄68.3[11.1]岁)匹配。
- 瘙痒(HR 0.695;95%CI 0.602-0.803;P<.001)、药疹(HR 0.755;95%CI 0.635-0.897;P=.001)、干燥症(HR 0.626;95%CI 0.469-0.834;P=.001)、非特异性皮疹(HR 0.704;95%CI 0.634-0.781;P<.001)及任何cirAE(HR 0.778;95%CI 0.726-0.834;P<.001)经Benjamini-Hochberg校正(显著性水平.05)后均与死亡风险降低显著相关。
- 银屑病(HR 0.703;95%CI 0.497-0.994;P=.045)与扁平苔藓/苔藓样皮炎(HR 0.511;95%CI 0.279-0.939;P=.03)亦显著。
- 湿疹性皮炎(HR 0.612;95%CI 0.314-1.195)、白癜风(HR 0.534;95%CI 0.254-1.123)、大疱性类天疱疮(HR 0.524;95%CI 0.140-1.956)及Grover病(HR 0.468;95%CI 0.115-1.898)均与强保护性临床效应相关。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Despite the efficacy of immune checkpoint inhibitors (ICIs), cutaneous immune-related adverse events (cirAEs) occur in 20% to 40% of all treated patients. To our knowledge, little is known about the predictive value of these cutaneous eruptions and their subtypes regarding cancer survival. OBJECTIVE: To determine the association of developing cirAEs following treatment with anti-programmed cell death 1 (PD-1) or anti-programmed cell death ligand 1 (PD-L1) therapy with patient survival. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used data from the TriNetX Diamond Network, a database of health records and claims data from more than 200 million US and European patients, to conduct a population-level cohort analysis. The study included 7008 eligible patients who developed cirAEs after treatment with anti-PD-1 or anti-PD-L1 therapy for malignant neoplasms of digestive organs, bronchus or lung, melanoma of skin, and urinary tract who were identified through the TriNetX Diamond Network along with 7008 matched controls. EXPOSURES: Development of cirAEs within 6 months following anti-PD-1 or anti-PD-L1 therapy. MAIN OUTCOMES AND MEASURES: A 6-month analysis using a Cox proportional hazards model was performed to determine the association of cirAEs with overall survival after adjusting for demographic characteristics, cancer type, and cancer stage. RESULTS: A total of 7008 patients (3036 women [43.3%]; mean [SD] age, 68.2 [11.2] years) were matched to 7008 (3044 women [43.4%]; mean [SD] age, 68.3 [11.1] years) controls. Pruritus (hazard ratio [HR], 0.695; 95% CI, 0.602-0.803; P < .001), drug eruption (HR, 0.755; 95% CI, 0.635-0.897; P = .001), xerosis (HR, 0.626; 95% CI, 0.469-0.834; P = .001), nonspecific rashes (HR, 0.704; 95% CI, 0.634-0.781; P < .001), and appearance of any cirAE (HR, 0.778; 95% CI, 0.726-0.834; P < .001) were significantly protective of mortality using a Benjamini-Hochberg correction with a significance level of .05. Additionally, psoriasis (HR, 0.703; 95% CI, 0.497-0.994; P = .045) and lichen planus/lichenoid dermatitis (HR, 0.511; 95% CI, 0.279-0.939; P = .03) were significant. Eczematous dermatitis (HR, 0.612; 95% CI, 0.314-1.195), vitiligo (HR, 0.534; 95% CI, 0.254-1.123), bullous pemphigoid (HR, 0.524; 95% CI, 0.140-1.956), and Grover disease (HR, 0.468; 95% CI, 0.115-1.898) were all associated with strong protective clinical effects. CONCLUSIONS AND RELEVANCE: The results of this cohort study suggest that the development of cirAEs is strongly associated with response to ICI therapy and patient survival.
引用
- Tang K, Seo J, Tiu BC, et al. Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy. JAMA Dermatol. 2022. PMID: 35019948. doi:10.1001/jamadermatol.2021.5476
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。